H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Cardiff Oncology (CRDF) to $13 from $14 and keeps a Buy rating on the shares. The firm says the initial CRDF-004 trial readout us expected by end of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDF: